A detailed history of Advisor Group Holdings, Inc. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 13,905 shares of OCUP stock, worth $13,626. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,905
Previous 21,555 35.49%
Holding current value
$13,626
Previous $32,000 43.75%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.19 - $2.07 $9,103 - $15,835
-7,650 Reduced 35.49%
13,905 $18,000
Q2 2024

Aug 13, 2024

BUY
$1.51 - $2.23 $7,619 - $11,252
5,046 Added 30.57%
21,555 $32,000
Q1 2024

May 10, 2024

SELL
$1.89 - $3.27 $1,512 - $2,616
-800 Reduced 4.62%
16,509 $33,000
Q4 2023

Feb 12, 2024

SELL
$2.59 - $3.64 $10,942 - $15,379
-4,225 Reduced 19.62%
17,309 $52,000
Q3 2023

Nov 13, 2023

SELL
$3.35 - $4.33 $37,637 - $48,647
-11,235 Reduced 34.29%
21,534 $72,000
Q2 2023

Aug 10, 2023

BUY
$3.63 - $6.38 $118,875 - $208,932
32,748 Added 155942.86%
32,769 $142,000
Q1 2023

May 12, 2023

SELL
$3.01 - $3.85 $10,535 - $13,475
-3,500 Reduced 99.4%
21 $0
Q4 2022

Feb 10, 2023

BUY
$2.04 - $3.53 $7,084 - $12,259
3,473 Added 7235.42%
3,521 $12,000
Q3 2022

Nov 14, 2022

SELL
$1.82 - $2.79 $15,875 - $24,337
-8,723 Reduced 99.45%
48 $0
Q2 2022

Aug 10, 2022

BUY
$1.8 - $3.25 $15,750 - $28,437
8,750 Added 41666.67%
8,771 $17,000
Q1 2022

May 04, 2022

SELL
$2.75 - $4.39 $1,100 - $1,755
-400 Reduced 95.01%
21 $0
Q3 2021

Nov 05, 2021

BUY
$3.84 - $5.38 $1,536 - $2,152
400 Added 1904.76%
421 $2,000
Q1 2021

May 13, 2021

BUY
$5.7 - $13.31 $22 - $53
4 Added 23.53%
21 $0
Q4 2020

Feb 10, 2021

BUY
$3.76 - $8.8 $63 - $149
17 New
17 $0

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $20.2M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.